References
- Taskesen E, Bullinger L, Corbacioglu A, . Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011;117:2469–2475.
- Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, . Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009;113:3088–3091.
- Dufour A, Schneider F, Metzeler KH, . Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010;28:570–577.
- Green CL, Koo KK, Hills RK, . Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010;28:2739–2747.
- Smith ML, Cavenagh JD, Lister TA, . Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 2004;351:2403–2407.
- Sellick GS, Spendlove HE, Catovsky D, . Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia 2005;19:1276–1278.
- Pabst T, Eyholzer M, Haefliger S, . Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008;26:5088–5093.
- Nanri T, Uike N, Kawakita T, . A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation. Genes Chromosomes Cancer 2010;49:237–241.
- Renneville A, Mialou V, Philippe N, . Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia 2009;23:804–806.
- Biggio V, Renneville A, Nibourel O, . Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML. Leukemia 2008;22:655–657.
- Fuchs O, Provaznikova D, Kocova M, . CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. Blood Cells Mol Dis 2008;40:401–405.